Since most mutations encountered in GD or GBA1-PD are missense mutations leading to misfolded enzyme, pharmacological chaperones which cross the blood-brain-barrier provide an attractive therapeutic strategy. The gene discussed is GBA1; the disease is Parkinson disease.